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ABSTRACT 
Introduction 
This protocol describes an observational study which set out to assess whether frailty and/or 
multi-morbidity correlates with short and medium term outcomes in patients diagnosed with 
COVID-19 in a European, multi-centre setting.  
Methods and analysis 
Over a 3-month period we aim to recruit a minimum of 500 patients across ten hospital sites, 
collecting baseline data including: patient demographics; presence of co-morbidities; 
relevant blood tests on admission; prescription of angiotensin converting enzyme inhibitors 
(ACEi)/ angiotensin receptor blockers (ARBs)/ non-steroidal anti-inflammatory drugs 
(NSAIDs)/ immunosuppressants; smoking status; Clinical Frailty Score (CFS); length of 
hospital stay; mortality and readmission. All patients receiving inpatient hospital care > 18 
years who receive a diagnosis of COVID-19 are eligible for inclusion. Long term follow up at 
6 and 12 months is planned. This will assess frailty, quality of life and medical complications. 
Our primary analysis will be short-term mortality and long-term mortality by CFS, adjusted for 
age (18-64, 65-80 and > 80) and gender. We will carry out a secondary analysis of the 
primary outcome by including additional clinical mediators which are determined statistically 
important using a likelihood ratio test. All analyses will be presented as crude and adjusted 
hazard ratio and odds ratio with associated 95% CIs and p values. 
Ethics and Dissemination 
This study has been registered, reviewed and approved by the following; Health Research 
Authority (20/HRA1898), Ethics Committee of Hospital Policlinico Modena 
(369/2020/OSS/AOUMO) Italy, Health & Care Research Permissions Service, Wales, NHS 
Research Scotland Permissions Co-ordinating Centre, Scotland. All participating units 
obtained approval from their local Research & Development department consistent with the 
guidance from their relevant national organisation.  
Data will be reported as a whole cohort. This project will be submitted for presentation at a 
national or international surgical and geriatric conference. Manuscript(s) will be prepared 
following the close of the project.  
 
 
 
 
 
 
 
 
Strengths and Limitations 
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 This is a large multi-centre study collecting data from throughout Europe 
 Data is collected by a network of clinicians with an established track record of 
research in frailty 
 Data collection is not entirely prospective. Some will be collected 
retrospectively. 
 Targeted data collection was carried out 
 
1. INTRODUCTION. 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) was 
identified in 2019 as a novel strain of pneumonia inducing virus. Coronaviruses have been 
identified since the 1960s, with other strains including severe acute respiratory syndrome- 
related coronavirus (SARS) in 2003 and Middle East respiratory syndrome- related 
coronavirus (MERS) in 2012 causing significant human harm and global spread. COVID-19 
has now been declared as a current worldwide pandemic [1] with predominant symptoms 
including: fever, cough and shortness of breath. The majority of people with COVID-19 have 
mild symptoms (81%), some develop severe illness requiring oxygen therapy (14%), with a 
smaller number requiring mechanical ventilation and/or intubation (5%) [2]. Early on in the 
pandemic, the most commonly reported presentation in severe COVID-19 was bilateral 
pneumonia [2]. Emerging literature has identified delirium, gastrointestinal disturbance and 
falls as predominant clinical signs in older, frail patients (3,4) 
 
Certain risk factors have been identified as predisposing patients to poor outcomes such as 
hospital admission, need for ventilation and subsequent death. Individuals with risk factors 
including older age and comorbidities such as hypertension, cardiovascular disease and 
diabetes mellitus, have an increased risk of severe disease poor outcomes in both COVID-
19 and non-COVID-19 populations [5, 6]. There has been speculation that drugs such as 
angiotensin converting enzyme inhibitors (ACEi) (eg ramipril, lisinopril, perindopril) and 
angiotensin receptor blockers (ARB) (losartan, candesartan), commonly taken by patients 
with hypertension, heart failure and diabetes mellitus, might increase susceptibility to 
coronavirus infection [7], as might other groups of drugs including non-steroidal anti-
inflammatory drugs (NSAIDs) and immunosuppressants. These could be simple association 
rather than causation given the common use of pharmacotherapy such as ACEi and ARBs in 
multimorbid individuals. Chronic musculoskeletal and respiratory diseases are common in 
our ageing population and as a result there is a high usage of NSAIDs (either prescribed or 
over-the-counter) and long-term steroids.  There is a theoretical possibility that 
immunosuppressants, such as steroids or other agents, used treat other conditions (e.g. 
renal disease, vasculitis, inflammatory bowel disease, transplant) confer benefit by modifying 
the host immune response to the virus resulting in less severe illness. [8]. 
 
Current professional guidelines recommend continuing these drugs [9,10]. This is based on 
a lack of available evidence that would clearly support withholding these medications during 
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the COVID-19 pandemic. By collecting data on these medications and their relationship to 
COVID-19 outcomes, we aim to improve on the current deficiency in evidence on whether it 
is safe to continue these medications, or whether they should be withdrawn. 
 
Frailty is recognised as a potential contributing factor to poor outcomes in COVID-19. Frailty 
is characterised by reduced physiological reserve [11] and defined as ‘a medical syndrome 
with multiple causes and contributors that is characterised by diminished strength, 
endurance and reduced physiological function that increases an individual’s vulnerability for 
developing increased dependency or death’ [12]. The frailty phenotype model categorises 
individuals into frail, pre-frail or not frail according to the presence of weight loss, self-
reported exhaustion, low energy expenditure, slow gait speed and weak grip strength [13]. 
The cumulative deficit model is validated to grade frailty in a person by identifying disability 
and comorbidity [14]. Frailty is associated with greater age, but not exclusively [15], and has 
been shown to correlate with adverse clinical outcomes including length of stay, mortality 
and institutionalisation. This association with frailty is present not only in geriatric medicine, 
but across a range of ages, specialties and interventions [16-19]. As a result, hospital teams 
are encouraged to routinely score frailty in adults [20, 21]. Frailty is more widely used than 
age alone as a trigger for specialist resource allocation, pathway decision aid and in shared 
decision making in older patients [22, 23]. Recent guidance from the National Institute for 
Clinical Excellence (NICE) recommended identification of frailty as part of a holistic 
assessment in facilitation of discussions with patients regarding critical care interventions in 
COVID-19  [24].  
 
Despite this, and due to the novel nature of COVID-19, no information is available on how 
frailty affects overall outcomes. Whilst evidence relating to factors which pose an increased 
risk of poor outcomes for patients with COVID-19 has begun to emerge globally [25-27], 
there remains a paucity of evidence relating specifically to the United Kingdom (UK) 
population. This study aims to provide evidence regarding some of the patient characteristics 
which might indicate poor outcomes, as applies to the UK population and healthcare 
systems.  It will provide valuable information about differences in care worldwide for the 
benefit of patients. Emerging narrative is demonstrating tentative links between both social 
deprivation and ethnicity on adverse outcomes in COVID-19 [28] therefore this information 
has been incorporated into baseline data collection in order to determine how outcomes 
across groups differed according to these characteristics.    
 
 
Currently ten hospitals, including one site in Italy have joined the study. The study remains 
open to new recruiting sites. Following ethical approval, we will advertise recruitment through 
the established clinical research networks in Geriatric Medicine (GemRes, based in 
Birmingham and WeGen based in Wales) and via social media, notably Twitter, a platform 
upon which a high level of interest in COVID-19 related healthcare developments has been 
evidenced. Other sites will be eligible to recruit subject to local approval. 
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Aims  
To assess whether frailty and/or multimorbidity correlates with poor clinical outcomes in adult 
patients diagnosed with COVID-19 virus in a multi-centre setting. 
The following research questions will be addressed: 
1. What are the outcomes for frail and/ or multi-morbid adults diagnosed with COVID-19, 
including length of hospital stay and mortality? 
2. What other factors influence outcomes in this setting, including medication, source of 
COVID-19 (community or nosocomial), socio-economic deprivation; ethnicity. 
2. METHODS. 
 
2.1 Study Summary 
Table 1 provides the summary of the COPE study information.  
Table 1: Study Summary 
Study Title COVID-19 in Older PEople – the influence of frailty 
and multimorbidity on survival. 
Short Title COPE study 
Study Design Observational 
Study Participants Adults aged 18 years and older, inpatients in an 
acute hospital setting with an illness relating to 
COVID -19 
Planned Size of Sample  minimum 500 
No of study sites Minimum 10 
Start date 27th February 2020. 
Planned Study Period 3 months 
Follow up duration  12 months 
Ethics/ registration No. Health Research Authority (20/HRA1898)  
Ethics Committee of Hospital Policlinico Modena 
(369/2020/OSS/AOUMO) Italy 
Health & Care Research Permissions Service, 
Wales 
NHS Research Scotland Permissions Co-ordinating 
Centre, Scotland 
Research Question/Aim(s) To assess frailty and multi-morbidity in older adults 
receiving acute inpatient care with a confirmed 
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 diagnosis of COVID -19. To correlate frailty with both 
short term and long-term outcomes. 
A secondary research question is the effect of ACEi, 
ARB, non-steroidal anti-inflammatory and 
immunosuppressive medications in COVID–19 
patients. 
A further research question is how other factors 
including source of COVID-19 (community vs 
nosocomial), socio-economic deprivation; ethnicity 
and gender influence outcomes in this setting. 
Longer term mortality, quality of life and adverse 
medical outcomes 
 
2.2 Study design and setting. 
Study setting: NHS hospitals in the UK and Worldwide partners (who will require separate 
local ethical compliance) that provide emergency care for patients diagnosed with COVID-19 
have been invited to participate. Our team, the Older Persons Surgical Outcomes 
Collaborative (OPSOC) (www.opsoc.eu) have widely collected data on frailty previously 
using routinely collected service evaluation level data, predominantly but not exclusively 
focussing on surgery in the older person. OPSOC has a proven record of conducting high 
quality research and successfully publishing results relating to outcomes for older people 
[29-32]. OPSOC has an international reputation, related specifically to the care of the frail 
older person. Using well established research networks and experience in collaborative 
research and frailty, we wish to explore outcomes for older patients with COVID-19 infection.  
Ten hospitals are already members of the OPSOC collaborative and are actively treating 
COVID-19 patients – Newport, Cardiff, Southmead Hospital Bristol, Bristol Royal Infirmary, 
Aberdeen Royal Infirmary, Royal Alexandra Hospital Paisley, Inverclyde Royal Infirmary, 
Salford Royal Hospital, Addenbrookes Hospital Cambridge, and Modena, Italy. The study 
will be open to other sites. 
Research will be conducted using the established surgical and geriatric registrar-led 
research networks [33,34].  The methodology for these networks is well described but in brief 
the networks provide local Principal Investigators (PI’s) that will co-ordinate local data 
collection and approvals in conjunction with Good Clinical Practice. These local leads act as 
a link between the local COPE team and the central Study Management Group (SMG). The 
Study Management Group will provide the ethical approvals, protocol and central 
organisation. Ultimately the SMG will analyse data and disseminate study findings, 
recognising all collaborators.   
 
2.3 Study population. 
Inclusion criteria: Any patient receiving inpatient hospital care with a clinical and/or 
laboratory confirmed diagnosis of COVID-19 aged 18 years and above 
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Exclusion criteria: Patients less than 18 years of age, and all patients aged 18 years and 
above without a clinically and/or laboratory confirmed diagnosis of COVID-19. 
Patient Screening: Patients will be screened for inclusion criteria by the local team. This will 
be undertaken by a range of health care professionals involved in direct patient care at each 
site. Hospital or National Health Service (NHS) number will not be entered into this form but 
will be kept separately with a key sheet.  
All transmission and storage of data will be encrypted and compliant with Health Insurance 
Portability and Accountability Act security guidelines. No patient identifiable information will 
be uploaded or stored on the secure database (password-protected login). Collaborators will 
anonymise patients by recording patient hospital numbers alongside database numbers in a 
separate secure spreadsheet to facilitate the collection of data locally. This database will be 
held within Cardiff University, Wales and stored for a minimum of 5 years. 
 
 
 
2.4 Variables collected. 
Baseline data 
► age, gender, deprivation score, ethnic origin 
► co-morbidities: coronary artery disease, diabetes mellitus, hypertension, and the 
prescription of ACEi or ARB, NSAIDs and immunosuppressive agents 
► smoking status (Never, Ex and Current) 
► blood tests on admission or at time of symptom development: albumin, c-reactive protein 
(CRP), estimated glomerular filtration rate (eGFR) 
► Clinical frailty score (CFS): 1-9 [supplementary Appendix A] 
 
Primary outcomes  
► Short-term mortality (measured at Day-7&&& and time-to- mortality) in frail vs non-frail 
patients with a COVID-19 diagnosis&& 
► Long-term mortality (measured at 6 and 12 Months and time-to-mortality) in frail vs non-
frail patients with a COVID-19 diagnosis&& 
 
Secondary outcomes  
► Time to discharge (Length of hospital stay), measured in days from time of admission 
and/ or time of COVID-19 diagnosis to discharge; 
► Effect of gender on outcomes in patients with COVID-19 
► 30-day readmission to local hospital& 
► Effect of certain drug classes on outcomes in patients with COVID-19& 
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► Effect of deprivation score and ethnicity on outcomes in patients with COVID-19& 
► Adverse outcomes and quality of life at 6 and 12 months 
&Due to the nature and need for rapid reporting the following outcomes will be subject to 
later data collection and may be reported separately from the primary research findings. 
&&Secondary Analysis studies will report the all-cause time-to-event as the primary outcome 
Frailty assessment 
We will use the Rockwood Clinical Frailty Score (supplementary Appendix A). This has been 
validated for use to assess frailty in older patients [14].  The score ranks from 1 to 9 with a 
score of ≥5 being classed as frail and 9 as terminally ill, and is based upon function 2 weeks 
prior to hospital admission. To ensure data quality each PI ensured adequate knowledge 
within the data collection team of frailty scoring using a short training video on how to 
complete the Clinical Frailty Scale 1-9. 
 
Longer Term Follow Up 
Follow up is planned via telephone assessment at both 6 and 12 months. This will aim to 
reassess frailty using the Clinical Frailty Score, quality of life assessments; Trauma 
screening questionnaire TSQ, ICECAP-O, PHQ visits to GP, hospital readmissions, 
significant events involving major organ systems (thromboembolic; respiratory (including the 
Medical Research Council Respiratory questionnaire, use of long term oxygen) and renal 
sequalae). 
 
 
2.5 Data management, Data protection and patient confidentiality  
All investigators and trial site staff will comply with the requirements of General Data 
Protection Regulation with regards to the collection, storage, processing and disclosure of 
personal information and will uphold the Data Protection Act’s core principles.  
 Where personal information is collected, it will be kept secure, and maintained. This will 
involve: 
 the creation of coded, depersonalised data where the participant’s identifying 
information is replaced by an unrelated sequence of characters 
 secure maintenance of the data and the linking code in separate locations 
using encrypted digital files within password protected folders and storage 
media 
 limiting access to the minimum number of individuals necessary for quality 
control, audit, and analysis 
 Confidentiality of data will be preserved when the data are transmitted to sponsors 
and co-investigators as patients will be assigned a study ID number. 
 Data collected from sites will be via the electronic database.  
 Data custodian is Dr Jonathan Hewitt. 
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 Only researchers who are directly involved in the data analysis will have full access 
to the study dataset (KM, BC, PB, SM, JH, PKM). 
 
 
2.6 Statistical Analysis and Sample Size. 
We will aim to recruit 500 patients; 50 patients across at least 10 sites. We estimated a 
minimum of 30% mortality in those that were frail, and 20% in those not frail (Hazard Ratio of 
0.60). In order to detect this difference with 80% power and with a 5% significance at least 
500 patients are needed to detect this difference. However, due to the emergent nature of 
this condition, it is envisaged that an interim analysis will be conducted as sample size 
increases. 
Statistical support will be provided by OPSOC. Data will be analysed for correlation between 
frailty and outcomes, including Day 7 and Day 90 mortality.  
Our primary analyses will measure mortality as the time-to-mortality using a mixed-effects 
Cox proportional hazards model, fitting site as a shared frailty (random intercept) to account 
for heterogeneity across different hospital sites.  
Co-primary analyses will include: mortality at the short term (Day 7), analysed with a mixed 
effects logistic regression at Day 7 mortality.  
The Secondary outcome: Time-to-discharge (herein described as length of stay), analyses 
as a time-to-event analysis consistent with the primary analysis. 
Secondary analyses will be adjusted for age group and gender, and other clinically important 
covariates. Other clinically important covariates will be included after discussion with the 
COPE investigators, once more information is known about the link between baseline 
covariates and their association with COVID-19 (e.g. comorbidities). We will carry out a 
secondary analysis of the primary outcome by including additional clinical mediators which 
are determined clinically important and presented as a final multivariable model. All analyses 
will be presented as adjusted OR with associated 95% CIs and p values. All other outcomes 
will be analysed as per the above analysis, but will be deemed secondary outcomes. 
Longer term time-points (e.g. Day 90) to be determined by the COPE investigators on 
receipt of further information from COVID-19 investigation. 
The time to mortality (or discharge) will be recorded from the date of admission, to the date 
of outcome and will be considered community acquired. Where a patient has a positive 
COVID-19 diagnosis that is reported fifteen days after admission (or later), they will be 
recorded as the date from diagnosis to outcome and considered as nosocomial infection.  
Missing data will be explored for symptomatic rationale and may be imputed after discussion 
with the COPE investigators. Subgroups for Age, sex, comorbidities may be explored to 
explain any mechanism of action found. 
Anticipated recruitment data will be collected at participating sites for all patients meeting the 
inclusion criteria over a 3-month period. Validation will be performed by local teams on 25% 
of data fields for 10% of cases. The validated fields will include key demographic and 
outcome data. 
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2.7 Study Management Group (SMG). 
This will be led by PKM (Aberdeen) and will involve reviewing safety data and, since the 
study collates observational data and there are minimal safety issues expected. 
2.8 Patient and Public Involvement (PPI)  
Due to the rapid onset of this pandemic and the urgency in analysis and dissemination of 
findings that will influence management of COVID-19 patients, it will not be possible to 
develop a PPI group of patients who have survived this illness. Many of them will remain 
clinically unwell, or in a period of self-isolation following COVID-19 infection.  Towards the 
end of the study, if medically appropriate, the sponsor site will invite a group of patients back 
to the hospital to discuss their experiences. This will enable identification of key areas into 
which further investigation is required. 
 
2.9 Role Of Study Sponsor And Funder. 
Aneurin Bevan NHS Trust, as the honorary NHS employer of the Chief Investigator (CI), has 
a critical role as part of the governance board of this project. Cardiff University (the CI’s 
substantive employer) is the Sponsor of the study. The sponsor is accountable for ensuring 
that the work is governed effectively and delivers the objectives that meet identified needs. 
The sponsor will control the final decision regarding the study design, conduct, manuscript 
writing and dissemination of results. 
The study at the time of writing has not received funding. 
 
3.0 Quality assurance and Indemnity. 
The quality of this study has been assessed by the following means:  
► Establishment of the Study Management Group. 
► Peer review by professionals with relevant expertise (Clinical trialists, nurses, frontline 
medical staff, statisticians, surgeons and geriatricians).  
► Review by team at Cardiff University (Sponsor Institution).  
► Safety reporting/adverse events will be reported by PIs. However, as this study involved 
routinely collected hospital data, we do not predict any. 
 
This is an NHS-sponsored research stud, therefore indemnity cover via HSG (96) 48 applies. 
 
3.1 Ethics and dissemination 
Ethical approval for the study was sought via proportional ethical review.  However, data 
collected are routinely recorded clinical data.  Therefore, the study was deemed not to 
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require ethical approval and approval for the study was granted by the Health Research 
Authority (HRA) in the UK (https://www.hra.nhs.uk/) . 
Subsequently, this study has been registered, reviewed and approved by the following 
organisations:  
► The HRA (Health Research Authority) for sites in England (20/HRA1898). 
► The NRSPCC (NHS Research Scotland Permissions Co-ordinating Centre) for sites in 
Scotland, with reciprocal approval was granted in Scotland by NRSPCC on 20th April 2020. 
► The Health & Care Research Permissions Service for sites in Wales 
► Ethics Committee of Hospital Policlinico Modena (369/2020/OSS/AOUMO) Italy 
All participating units must obtain approval from their local Research & Development 
department consistent with the guidance from their relevant national organisation: 
The project will therefore be registered locally with the NHS Trust or Health Board or 
Institutional Research & Development department prior to commencing patient identification 
and data collection at each site. It is the responsibility of the local COPE Study team to 
ensure that local Research and Development approvals are in place prior to commencing 
data collection.  
 
All data will be reported as a whole cohort. Unit level data for comparison will be fed back to 
collaborators to support local service improvement. This project will be submitted for 
presentation at a national or international surgical and geriatric conference. Manuscript(s) 
will be prepared following the close of the project.  Manuscripts will also be prepared 
following interim data analysis if numbers of patients recruited to the study at that time 
exceed the stated sample size.    
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